FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With CtDNA-Guided Treatment
May 16, 2026
May 16, 2026
SOUTH SAN FRANCISCO, California, May 16 -- Genentech, a member of Roche Group, issued the following news release:
* * *
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
* First approved ctDNA MRD-guided therapy reinforcing Genentech's commitment to innovation and practice-changing precision medicine
* New treatment approach enables healthcare professionals to tailor treatment w . . .
* * *
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
* First approved ctDNA MRD-guided therapy reinforcing Genentech's commitment to innovation and practice-changing precision medicine
* New treatment approach enables healthcare professionals to tailor treatment w . . .